Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023,...
2023-10-17 16:34:51 ET Amneal Pharmaceuticals ( NYSE: AMRX ) said that it plans to reorganize and simplify its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure. The biotech company said it intends to convert to a more traditional c...
- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
2023-09-24 07:37:29 ET Summary Amneal Pharmaceuticals exhibits strong Q2 performance with $599M in revenue and diversification in generics and biosimilars. However, its $2.59B long-term debt overshadows growth, raising concerns over liquidity and future financing options. Inve...
2023-09-06 18:16:56 ET More on Amneal Pharmaceuticals Seeking Alpha’s Quant Rating on Amneal Pharmaceuticals Historical earnings data for Amneal Pharmaceuticals Financial information for Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2023 Q2 - Res...
- Key injectable currently on the U.S. FDA shortage list - Received Competitive Generic Therapy approval designation Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application...
- 1 st product approval in China represents Amneal’s entry in second largest pharmaceutical market - Expects international expansion will be another key vector for long-term growth and impact Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the ...
- Key ADHD medicine on the U.S. FDA shortage product list - Represents another high-value product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Applicatio...
- Senior members of the U.S. Government Visit One of Amneal’s 12 Manufacturing Sites Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...